CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Pharma Pulse 5/20/25: Balancing Benefits, Risks, and Public Perception with HPV Vaccinations; Pfizer-Backed CellCentric Secures $120M for Further Myeloma Trials

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

CellCentric raises £90m to prevent cancer deaths

Cancer-fighting MedTech CellCentric has raised £90m in fresh funding. The Series C round will support the advancement of the Cambridge company’s oral treatment for multiple myeloma, inobrodib. The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm. Despite significant recent progres…

CellCentric Raises $120M In Series C Funding

CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, raised $120M in Series C funding. The round was led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm. Led by CEO Will West, CellCentric is a clinical stage […] The post CellCentric Raises $120M In Series C Funding appeared first …